Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965573 | 0.94 | POLB (0.41) | POLBCYP11B1CYP11B2HTR2AHTR2C | |
| SCHEMBL3965730 | 0.80 | PPARD (0.46) | CYP11B1CYP11B2HSD17B1KDM4CMAOA | |
| SCHEMBL3968890 | 0.79 | CYP11B1 (0.38) | CYP11B1CYP11B2HSD17B1PDE4BMAOA | |
| SCHEMBL3964872 | 0.79 | THRA (0.38) | HTR2AHTR2CHTR2BHSD17B1THRA | |
| SCHEMBL3965850 | 0.78 | CYP11B1 (0.42) | POLBCYP11B1CYP11B2HSD17B1PDE4B | |
| SCHEMBL3964420 | 0.76 | HSD17B1 (0.44) | CYP11B1CYP11B2HTR2AHTR2CHTR2B | |
| SCHEMBL3969570 | 0.74 | PPARD (0.52) | HSD17B1MAOAMAOB | |
| SCHEMBL3961926 | 0.74 | HTR2A (0.52) | HTR2AHTR2CHSD17B1 | |
| SCHEMBL10530719 | 0.74 | CYP4F2 (0.47) | CYP11B1CYP11B2HSD17B1KDM4C | |
| SCHEMBL3965811 | 0.74 | CYP11B1 (0.40) | CYP11B1CYP11B2HSD17B1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | POLB 3626/4885CYP11B1 44/4885CYP11B2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.